Profile data is unavailable for this security.
About the company
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
- Revenue in CHF (TTM)577.77m
- Net income in CHF113.57m
- Incorporated1971
- Employees2.01k
- LocationBachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
- Phone+41 619352333
- Fax+41 619352324
- Websitehttps://www.bachem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus plc | 753.00m | 8.89m | 1.32bn | 3.44k | 149.72 | 2.14 | 23.74 | 1.75 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.84 | 194,475.10 | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.21 | 93.17 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| Evotec SE | 727.34m | -160.41m | 1.42bn | 5.01k | -- | 1.57 | -- | 1.96 | -0.9668 | -0.9668 | 4.39 | 5.46 | 0.3661 | 19.82 | 5.22 | 153,537.30 | -8.07 | -0.0064 | -9.86 | -0.0076 | 13.70 | 24.51 | -22.05 | -0.0178 | 1.99 | -3.11 | 0.3268 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| Galapagos NV | 284.23m | -56.73m | 1.59bn | 683.00 | -- | 0.5944 | -- | 5.60 | -0.9096 | 3.14 | 4.61 | 43.44 | 0.0704 | 0.3157 | 6.58 | 470,055.70 | -1.41 | -1.48 | -1.55 | -1.65 | 65.10 | -- | -19.96 | -14.42 | 9.95 | -- | 0.004 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| BB BIOTECH AG | 270.66m | 125.36m | 2.16bn | -- | 17.10 | 0.9544 | -- | 7.98 | 2.27 | 2.27 | 4.95 | 40.66 | 0.1077 | -- | -- | -- | 4.99 | 2.34 | 5.64 | 2.52 | 97.86 | 99.06 | 46.32 | 35.40 | -- | 2.17 | 0.1096 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| BACHEM HOLDING AG | 577.77m | 113.57m | 5.58bn | 2.01k | 49.01 | 4.27 | 34.65 | 9.66 | 1.52 | 1.52 | 7.71 | 17.42 | 0.3585 | 1.06 | 4.33 | 288,020.40 | 7.05 | 8.85 | 8.10 | 10.28 | 31.04 | 31.63 | 19.66 | 19.74 | 1.57 | 100.82 | 0.0002 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Zealand Pharma A/S | 9.65m | -132.07m | 7.27bn | 298.00 | -- | 6.49 | -- | 753.94 | -16.69 | -16.69 | 1.21 | 125.74 | 0.013 | 3.73 | 0.2625 | 303,834.00 | -17.83 | -42.74 | -18.63 | -50.24 | 72.06 | 96.13 | -1,369.25 | -464.66 | 35.49 | -- | 0.042 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Qiagen NV | 1.74bn | 82.35m | 8.46bn | 5.90k | 104.68 | 2.69 | 31.58 | 4.85 | 0.3863 | 0.3863 | 8.33 | 15.04 | 0.3229 | 2.03 | 5.71 | 311,945.20 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Genmab A/S | 2.48bn | 582.10m | 12.88bn | 2.64k | 21.74 | 3.09 | 34.55 | 5.20 | 71.38 | 71.38 | 303.48 | 502.60 | 0.5277 | 10.98 | 3.37 | 8,966,878.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of Nov 14 2024. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF
17.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| VV Verm�gensverwaltung AGas of 30 Aug 2024 | 3.64m | 4.85% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 3.01m | 4.02% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 1.34m | 1.78% |
| UBS Asset Management Switzerland AGas of 30 Sep 2024 | 1.13m | 1.51% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.08m | 1.43% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 1.03m | 1.37% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 772.86k | 1.03% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 555.20k | 0.74% |
| Pictet Asset Management SAas of 30 Jun 2024 | 421.17k | 0.56% |
| GAM Investment Management (Switzerland) AGas of 31 Jul 2024 | 379.42k | 0.51% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
